Background
Type 2 diabetes mellitus (T2DM) is a chronically metabolic syndrome characterized by insulin resistance and pancreatic β cell dysfunction, caused by inherited and/or environmental factors [
1]. The global burden of diabetes is increasing worldwide, and the number of diabetic patients is expected to rise to 578 million by 2030 and to 700 million by 2045 [
2]. Thus, an effective control of blood glucose is the key to prevent complication. Currently, many medicines are listed on the market to treat diabetes, including insulin, metformin, α-glucosidase inhibitors, thiazolidinediones and sodium-glucose transport protein 2 [
3]; however, these treatments are leading to possible side effects, e.g. gastrointestinal discomfort and hypoglycemia [
4,
5].
Traditional Chinese medicine (TCM) having less side-effect and irritation in general has been proposed in treating diabetic patients [
6]. In particular, the formulated herbal mixtures have been commonly used in clinics for medical treatment. Among thousands of herbal formulae of TCM, Danggui Buxue Tang (DBT) is one of the simplest. DBT was first described in < <
Neiwaishang Bianhuo Lun > > by Li Dongyuan in AD 1247 in China. He described DBT should have: Astragali Radix (AR; roots of
Astragalus memebranaceus (Fisch.) Bunge var.
mongholicus (Bunge) Hsiao) and Angelicae Sinensis Radix (ASR; roots of
Angelica sinensis Oliv.) in 5 to 1 ratio. This herbal mixture has been utilized for nourishing “Qi” and enriching “Blood” for women suffering from menopausal symptoms. Pharmacologically, DBT is able to mitigate menopausal symptoms [
7‐
10], to stimulate immune responses [
11] and to accelerate bone regeneration [
12,
13]. In addition, DBT has been found to alleviate insulin resistance and to relieve diabetic complication [
14‐
16].
Calycosin-7-O-β-D-glucoside and ononin (a 7-O-β-D-glucopyranoside of formononetin) are two major flavonoid glucosides in DBT [
17], and which are reported to have potential efficacy associated with diabetes [
18]. The pharmacological efficacy of flavonoid glucosides is usually ascribed to their corresponding aglycones that are absorbed much easier than their glycoside forms [
19,
20]. The de-glycosylation, triggered by β-glucosidase located in the human small intestine, is regarded as a critical process in improving metabolism of flavonoid glucosides [
21,
22]. As a result, the aglycones can be absorbed effectively into blood circulation in attributing anti-diabetic functions [
23].
In order to deglycosylate flavonoid glucosides to their corresponding aglycones, as well as to increase intestinal absorption of bioactive compounds, we adopt a bio-conversion method in vitro by means of microbial fermentation in a herbal mixture. Indeed, microorganisms have been employed in fermenting TCM, e.g. probiotic was used to ferment Scutellaria Radix [
24], Atractylodis Macrocephalae Rhizoma [
25] and red ginseng [
26]. To improve the efficacy of DBT in fighting against diabetes, we developed a fermentation process of herbal extract together with
Lactobacillus plantarum, a Gram-positive
Lactobacillus, commonly found in fermented food products [
27]. Thereafter, we compared the activities of fermented product against its parental herbal extract, which included: (i) the amounts of flavonoid glucosides and its aglycones; and (ii) the inhibitory activities of α-glycosidase, α-amylase, pancreatic lipase, antioxidant capacity and non-enzymatic glycation.
Materials and methods
Chemicals and reagents
Standards of calycosin-7-O-β-D-glucoside, ononin, calycosin, formononetin and rutin (Internal standard, IS) were supplied by Testing Laboratory for Chinese Medicine of HKUST (Hong Kong, China). The purity of each standard was > 98%, as detected by HPLC-DAD and 13C-NMR analysis. The HPLC grade acetonitrile and formic acid were obtained from Merck (Darmstadt, Germany). Deionized water (18 MW/cm) was supplied with a Direct-Q water purification system (Millipore, Milford, MA). Acquity UPLC C18 column (Waters, Milford, MA). Tris, p-nitrophenol (PNP), p-nitropheny-β-D-glucopyranoside (PNP-D-Glu), α-glucosidase, p-nitrophenyl-α-D-glucopyranoside, bovine serum albumin (BSA) and O-phenylenediamine were purchased from Macklin Biochemical (Shanghai, China). DPPH was gained from TCI Chemical Industry (Shanghai, China). Other materials were obtained from Sigma-Aldrich (St. Louis, MO).
Preparation of herbal decoction
The roots of three-year-old
A. memebranaceus var.
mongholicus (Astragali Radix; Huangqi; AR) from Shanxi Province [
28] and two-year-old
A. sinensis roots (Angelicae Sinensis Radix; Danggui; ASR) from Minxian of Gansu Province [
29] were collected in 2019. The herbs were identified morphologically by Dr. Tina TX Dong. The voucher specimens of AR (Lot: 20190320) and ASR (Lot: 20190412) were recorded in HKUST Shenzhen Research Institute. In preparing DBT, AR and ASR were weighed according to a ratio of 5:1 and then mixed well. The mixture was boiled in 8 volumes of water (v/w) for 2 h, and the extraction was repeated twice [
12]. The extracts were dried by lyophilization and stored at − 80 °C. The chemical analysis of fermented DBT was carried out as described [
8].
L. plantarum (GDM 1.191), a facultative heterofermentative lactic acid bacteria, was purchased from Guangdong Microbial Culture Collection Center (ACCC11095; Guangdong, China).
L. plantarum is commonly found in most fermented foods [
30]. The culture was inoculated twice in MRS broth (10 g peptone, 8.0 g lab-lemco’ powder, 4.0 g yeast extract, 20 g glucose, 2.0 g di-potassium hydrogen phosphate, 2.0 g tri-ammonium citrate, 5.0 g sodium acetate with 3 H
2O, 0.2 g magnesium sulphate, 0.04 g manganese sulphate with 4 H
2O, and 1 mL Tween in 80 L of water, pH 5.7 ± 0.2; from Hopebio, Qingdao, China) at 37 °C in anaerobic atmosphere (10% H
2, 10% CO
2, 80% N
2) for 24 h to obtain the strain at end of exponential phase. A stock solution of DBT herbal extract was sterilized with a filter, and which was diluted with MRS medium. The inoculation of
L. plantarum was adjusted to a concentration of 1 × 10
8 CFU/mL, and the fermentation was performed at 37 °C under anaerobic condition, shaking in 100 rpm, until the late stationary phase. The growth of
L. plantarum was determined by absorbance at 595 nm.
UPLC-MS/MS analysis
The stock solutions of calycosin-7-O-β-D-glucoside, ononin, calycosin and formononetin were freshly prepared in methanol at 1 mg/mL. Mixed stock solution (200 μg/mL each) was prepared. Rutin (IS) at 20 μg/mL was diluted from the stock in methanol. The working standard solutions (0.092–200 μg/mL) for analytes were prepared by a serial diluent of mixed stock solution with methanol. The calibration standard solutions (0.023–50 μg/mL) for analytes were prepared by spiking an appropriate amount of working standard solutions into 150 μL blank matrix. The QC concentrations of tested samples were selected in 0.068, 1.84, and 16.6 μg/mL, respectively, at low, medium and high levels. The sample after fermentation (200 μL) and IS (50 μL) were shaken with vortex for 30 s. Then, adding 800 μL methanol to the mixture, vortexed for 2 min and centrifuged at 10,000 rpm for another 10 min. Then, 2 μL supernatant was subjected to UPLC-MS/MS analysis.
UPLC chromatograph coupled with a PerkinElmer QSight®210 MS/MS detector (PerkinElmer, Waltham, MA). The instrument control, analysis and data processing were performed using Simplicity 3Q™ software platform. Sample separation was achieved on an Acquity C18 column (4.6× 50 mm, 1.7 μm) with a constant flow rate of 0.3 mL/min at 30 °C. The mobile phase was composed of water (0.1% formic acid, A) and acetonitrile (C), using a gradient elution of 80-60% A at 0–4 min, 60-10% A at 4–6 min, 10-10% A at 6–7 min, 10-80% A at 7–8 min, 80-80% A at 8–10 min. The injected volume was set at 2 μL. The acquired parameters were optimized as follows: drying gas value, 100; nebulizer gas value, 150; electrospray voltage, 5500 V; HSID temperature, 280 °C. The detection was recorded as MRM negative mode. The proposed analytical method was validated and calculated for specificity, linearity, intra-day and inter-day precision, accuracy, extraction recovery, matrix effect and stability, according with the criteria described in the FDA guidelines for bioanalytical samples.
Enzymatic assays
β-glycosidase
The assay for β-glycosidase activity was conducted according to the reported method with minor modifications [
31]. Briefly, 100 μL fermented sample was acquired by centrifuging at 10,000 rpm for 10 min. The reaction mixture (1.0 mL) comprised of 1 mM p-nitropheny-β-D-glucopyranoside (PNP-D-Glu), 0.1 M phosphate buffer (pH 6.8) and the sample was incubated at 37 °C for 30 min. The reaction was stopped by adding 500 μL of 0.5 M NaOH centrifuged at 10,000 rpm for 10 min. The amount of PNP released was measured by absorbance at 405 nm in a microplate reader.
α-Glucosidase
The α-glucosidase inhibitory property was performed according to the previous method with modification [
32]. The tested sample, diluted 5 times with water, was vortexed at 3000 rpm for 5 min. The reaction mixture was composed of the tested sample, phosphate buffer (0.1 M, pH 6.8) and α-glucosidase (50 μg/mL). Next, p-nitrophenyl-α-D-glucopyranoside solution (10 mM) was added to the mixture. The incubation was continued for 20 min at 37 °C, and which was stopped by adding 100 mM Na
2CO
3 solution. Acarbose was used as a positive control at 1 μg/mL. The reaction was measured by monitoring 405 nm. The results were presented as a percentage of α-glucosidase inhibition, calculated according to the following equation:
\( {\text{Inhibition }}\left( \% \right) \, = \, ({}{\text{OD}}{}\_\left( {{\text{ctrl}}.} \right) - {}{\text{OD}}{}\_{\text{sample}})/{}{\text{OD}}{}\_({\text{ctrl}}.) \, \times { 1}00\%\).
α-Amylase
The activity of α-amylase was measured using a modified method [
33]. Briefly, the tested sample and α-amylase solution (0.2 U/mL) were incubated at 37 °C for 30 min. Next, 2% soluble starch solution was added to the mixture, and the incubation was continued for another 20 min at 37 °C. HCl (1 M) was added to terminate the enzymatic reaction, followed by iodine reagent (5 mg/mL). Acarbose (200 μg/mL) was used as a positive control. The absorbance was measured at 620 nm, and the percent of inhibition was calculated.
Pancreatic lipase: The pancreatic lipase activity was performed using PNPP as substrate [
34]. PNPP was used as a substrate in a solution containing: 40 mg PNPP in isopropanol added to 50 mM Tris–HCl buffer (pH 8.0), 40 mg gum Arabic, 80 mg sodium deoxycholate, and Triton X-100. Orlistat (50 μg/mL) was used as a positive control. Briefly, 20 μL of the tested sample was put into 96-well plates, and lipase enzyme solution (10 mg/mL; porcine pancreatic lipase type II, Sigma-Aldrich) was freshly prepared in 50 mM Tris-HCl buffer (pH 8.0), stirred until fully dissolved and was then added 80 μL to all tests. After 37 °C for 15 min, the substrate solution was added at 37 °C for 25 min. Absorbance was recorded at 405 nm.
Antioxidant activity
DPPH radical-scavenging capacity was estimated according to a previous protocol [
35]. Vitamin C (100 μg/mL) was used as a positive control. Briefly, 80 μL of each tested sample and 800 μL DPPH (0.5 mmol/L) solubilized in a methanol solution were vortex-mixed and incubated in the dark at 37 °C for 20 min. DPPH radical was determined by measuring the absorbance at 517 nm. Total antioxidant capacity (T-AOC) was measured by biochemical methods following the manufacturer’s instructions (Beijing Solarbio Science and Technology, Beijing, China) [
36].
Anti-glycation assay
The lysine-glucose Maillard reaction was determined, as recorded previously [
37]. Glutamic acid and lysine (both at 1.0 M, 0.2 mL) were mixed with 0.8 mL of tested samples in sodium phosphate buffer (0.1 M, pH 6.8) and 0.5 mL of 0.25 M sodium phosphate buffer at 70 °C for 2 h. Aminoguanidine (10 mg/mL) was used as a positive sample. The absorbance was measured at 450 nm on a microplate reader. The anti-glycation assay in the BSA-fructose model was performed as described [
38]. Fructose (1.5 M, 0.5 mL) was mixed with 0.5 mL tested sample, 2.0 mL sodium phosphate buffer (0.1 M, pH 6.8, with 0.02% sodium benzoate.) at 37 °C for 2 h. BSA (30 mg/mL, 0.5 mL) was added at 37 °C for 5 days. Aminoguanidine (1 mg/mL) was used as a positive control. The fluorescent advanced glycation end-product (AGE) was monitored (350 nm as the excitation /420 nm as emission) using a fluorescence spectrophotometer. Methylglyoxal (60 mM, 0.5 mL) was mixed with 0.5 mL tested sample and 2.0 mL of sodium phosphate buffer (0.1 M, pH 6.8, with 0.02% sodium benzoate) at 37 °C for 2 h. BSA (30 mg/mL, 0.5 mL) was added at 37 °C for 5 days. Aminoguanidine (1 mg/mL) was used as a control. The fluorescent AGE was monitored (350 nm as the excitation /420 nm as emission) was measured on the fluorescence spectrophotometer. In arginine-methylglyoxal assay, methylglyoxal (60 mM, 0.5 mL) was mixed with 0.5 mL of tested samples and 2.0 mL sodium phosphate buffer (0.1 M, pH 6.8, with 0.02% sodium benzoate.) at 37 °C, 2 h. Arginine (60 mM, 0.5 mL) was added to all sets, and the mixtures were incubated at 37 °C for 5 days. Aminoguanidine (1 mg/mL) was used as a positive sample. Then, the fluorescent AGE was monitored (350 nm as the excitation /420 nm as emission) was measured.
Methylglyoxal scavenging
Methylglyoxal scavenging was conducted by HPLC method according to a previously published method with modification [
39]. Methylglyoxal was derivatized with O-phenylenediamine (O-PD) to form 2-methylquinoxaline (2-MQ), highly specific for methylglyoxal. Methylglyoxal and O-PD were dissolved in phosphate buffer (0.1 M, pH 6.8) to 10 and 50 mM. Aminoguanidine (1 mg/mL) was used as a control. The mixture of methylglyoxal (50 mM, 0.1 mL) with the sample (0.4 mL) was incubated at 37 °C for 4 h. Then, O-PD (0.2 mL) was added into all sets. The samples were kept for 30 min for undergoing derivatization reaction between methylglyoxal and O–PD. Analysis of 2-MQ was performed on a Waters 2695 HPLC platform (Waters Corporation, Milford, MA) and carried out by a Zorbax SB-C18 column (4.6 × 250 mm, 5 μm, Agilent Technologies, Palo Alto, CA). The mobile phase for HPLC system consisted of pure methanol (solvent A) and pure Millipore water (solvent B) with a constant flow rate set at 1.0 mL/min. An injection volume was 10 μL. The linear gradient for elution was: 0–35 min, 5–100% A; 35–45 min, 100–5%; followed by 5 min to re-equilibrate the system. 2-MQ was detected at 315 nm using a DAD detector having a retention time at 20.09 min. The peak area of 2-MQ in each sample was integrated. The methylglyoxal scavenging was calculated using the percentage (%) calculated from the homologous equation in BSA-fructose model.
Discussion
Fermentation of L. plantarum together with a Chinese herbal mixture DBT could enhance the bacterial growth, as well as the chemical transformation of herbal extract. In chemical transformation, the major flavonoid glucosides of DBT were hydrolyzed into their corresponding aglycones: this conversion was mediated by β-glucosidase deriving from fermented bacteria. For the first time, we have utilized L. plantarum bacteria in strengthen the pharmacological efficacy of DBT. The fermented DBT showed better effects in anti-diabetic functions, which included: (i) inhibitory properties on α-glucosidase; (ii) antioxidant properties on DPPH scavenging and T-AOC; and (iii) anti-glycation capacity on various models. This fermentation approach, nevertheless, could be considered as a mean to enhance the pharmacological efficacy of TCM in general. The safety should not be a concern: because L. plantarum is a common Lactobacillus found in many fermented food products, as well as in human saliva, which has been known to show no harm to our body. Having this new direction of fermentation of Chinese herbal extract therefore can pave another method to enhance the product efficacy, in particular Lactobacillus and herbal product are commonly used as health food products on the market.
The UPLC-MS/MS analysis is a common method for simultaneous quantitation of flavonoid compounds. However, most of the developed methods are focusing on herbal or plasma samples. No reports have investigated the simultaneously quantitative analysis of the flavonoids in the fermented broth of L. plantarum. The method development of MS parameters, as well as method validation comprising parameters, e.g. specificity, linearity, sensitivity, precision and accuracy, extract efficiency, matrix effects and stability, is being described in detail at the present study. Thus, a sensitive and reliable quality control method using MRM in negative ion mode for simultaneous determination of four flavonoids in fermented DBT, i.e. calycosin-7-O-β-D-glucoside, ononin, calycosin and formononetin, has been developed.
The chemical transformation, i.e. cleavage of the sugar moieties, was observed in here. The enzyme β-D-glucosidase is responsible for the cleavage of β-D-glycosidic linkages, releasing glucose moieties from flavonoid glycosides [
39]. This enzyme should derive from the cultured medium of
L. plantarum, not from the herbal extract. The expression of β-D-glucosidase in the fermented product, as revealed by release of p-nitrophenol from p-nitropheny-β-D-glucopyranoside, could be markedly enhanced in DBT extract. A synergy during the fermentation of DBT with
L. plantarum is being proposed here. First, DBT promoted the expression of β-D-glucosidase in fermenting
L. plantarum. Second, the produced β-D-glucosidase hydrolyzed the flavonoid glycosides of DBT to aglycons. These findings suggested that an improvement in hydrolysis rate of glycoside enzymes perhaps may be ascribed to DBT inducement. In TCM preparation, the phytochemicals exhibit low oral bioavailability, in particular glycosides are possessing poor membrane permeability [
40]. Moreover, these glycosides are inevitable to be transformed by microbial hydrolysis in intestinal before their absorption to the gut [
41]. Herein, the role of β-D-glucosidase in food and/or pharmaceutical bioprocessing could promote aglycone entering blood circulation [
42].
The anti-diabetic functions of fermented products should be derived from DBT. The chemical changes within DBT after fermentation could account for increased pharmacological efficacy. However, the identity of active chemicals of DBT in triggering these activities are not resolved. The increased antioxidant property could be accounted for the hydrolyzed flavonoid glycosides. Indeed, aglycons in the herbal extract were shown to have stronger antioxidative activity [
43]. Although we have shown the increased calycosin and formononetin being generated from calycosin-7-O-β-D-glucoside and ononin, respectively, in the fermented DBT, the amounts of total aglycons should be more than that, i.e. other flavonoid glycosides in DBT should be undergone the transformation. In our preliminary results of the four AR flavonoids, the increased activities however could not be fully accounted by completed hydrolyzed of calycosin-7-O-β-D-glucoside and ononin. The inhibitory properties of α-glucosidase and glycation increased in the fermented DBT. The α-glucosidase inhibitory activity from natural products has been proposed to be accounted by flavone, in particular isoflavone [
44]. In line to our current result of chemical conversion, flavonoid glucosides possessed a relatively poor inhibitory action on α-glucosidase, as compared with their corresponding aglycones [
40].
The non-enzymatic glycation, a spontaneous reaction between sugar and protein, is considered as a source of oxidative stress, as well as the primary route in forming AGEs. Increased AGE has been implicated in the pathogenesis of diabetic complication. The increased anti-glycation activity in fermented DBT could be accounted by the conversion of flavonoid glucosides to aglycons. Various phenolic compounds, inhibiting α-glucosidase, have been reported as inhibitors of glycoside hydrolase due to their binding with proteins, as such to erode the glycation reaction [
38]. The hydrolysis of polysaccharides within DBT during fermentation could be another cause of the increased anti-glycation activity; however, this notion has to be further illustrated.
Conclusions
To the best of our knowledge, we have reported for the first time, the conversion of calycosin-7-O-β-D-glucoside and ononin to their aglycons in DBT through a fermentation process using L. plantarum. In considering the traditionally oral intake of herbal medicine, the conversion of flavonoid glycosides in fermented DBT not only improves the absorptivity of flavonoids to gut, but which possess prominent activities against α-glucosidase, antioxidant and anti-glycation. These anti-diabetic activities could be accounted, at least partially, by the increased flavonoid aglycons in the fermented products. The result paves direction for fermentation of herbal extract, as to strengthen its pharmacological properties.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.